Post de Ability Biologics

Plus de 170 conjugués anticorps-médicaments (CDA) sont en développement clinique, une augmentation de 90 % par rapport à l'année précédente. Ils offrent des avantages comme l'amélioration des résultats et la réduction des effets secondaires, cependant, ils font face à des défis, notamment techniques et de sécurité. Pour en savoir plus, découvrez notre article détaillé sur le sujet ! 📖

Precision oncology can assist in enhancing clinical results and patients' quality of life with lesser adverse effects. The need to find more molecular targets, improve treatment accessibility and affordability, address health disparities, and resolve ethical concerns with this approach are just a few of the many difficulties precision oncology development faces. By focusing on companion diagnostics to identify the most qualified patients for clinical trials and treatments, precision oncology can lower R&D expenses and boost the return on investment of oncology drugs. Additionally, it can assist in testing the efficacy and safety of treatments in a variety of representative populations using real-world data.

L’individualisation des posologies doit être considérée comme un aspect primordial de l’oncologie de précision ! Celle-ci est trop souvent considérée comme se résumant à prendre en compte la génétique tumorale dans la prescription, en ignorant que ce qui détermine l’efficacité aussi bien que la toxicité d’un traitement, c’est la dose administrée et l’exposition circulante que celle-ci occasionne ! Merci à Nicolas Widmer et Monia Guidi de m’avoir associé à porter avec eux ce numéro spécial de Pharmaceutics consacré à la pharmacocinétique de population des anticancéreux, qui réunit un bouquet de travaux originaux sur ce sujet.

Online!🚦 #EMID2 is a novel biotherapeutic for aggressive cancers identified by in vivo screening -------------------------------------------------------------- New drugs to tackle the next pathway or mutation fueling cancer are constantly proposed, but 97% of them are doomed to fail in clinical trials, largely because they are identified by cellular or in silico screens that cannot predict their in vivo effect. Here Serena Zacchigna et al. screened an Adeno-Associated Vector secretome library (> 1000 clones) directly in vivo in a mouse model of cancer and validated the therapeutic effect of the first hit, EMID2, in both orthotopic and genetic models of lung and pancreatic cancer. The Authors concluded that EMID2 overexpression inhibited both tumor growth and metastatic dissemination, consistent with prolonged survival of patients with high levels of EMID2 expression in the most aggressive human cancers. Full paper 👇 https://lnkd.in/dQ7vwMaJ #MouseModel #GeneTherapy #Biotherapeutics #LungCancer #PancreaticCancer IFO - Istituto Nazionale Tumori Regina Elena - Istituto Dermatologico San Gallicano

#tnbc #cancerdusein une nouvelle combinaison de médicaments existants decouverte pour lutter conter le cancer du sein triple negatif. La recherche se concentre sur les combinaisons de medicaments pour lutter contre cette forme de cancer. Avec des medicaments existants les essais cliniques peuvent etre plus simples à lancer.

If you missed these abstracts or the poster presented, let me bring it to your attention. Promising results!

📢 Latest Update 🔊 AVM Biotechnology is pleased to announce its participation in the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago, IL from May 31st to June 4th, 2024. AVM Biotechnology is having 2 abstracts and 1 poster at the meeting: #ABSTRACTS 1. Durable complete response and overall survival in heavily pretreated, poor prognosis Non-Hodgkin’s Lymphoma to immunoactivating AVM0703 with few and mild drug-related adverse effects. 2.AVM0703 treatment overcomes the limitations of R-CHOP and improves survival in a model applicable to ABC subtype DLBCL #POSTER #7077 - Durable complete response and overall survival in heavily pretreated, poor prognosis Non-Hodgkin’s Lymphoma to immunoactivating AVM0703 with few and mild drug-related adverse effects (June 3rd, 9:00 AM – 12:00 PM) AVM Biotechnology has brought its lead drug, #AVM0703, from the most basic discovery research to Phase 2 clinical trials (no safety signal yet) and has established a very active, successful compassionate use/expanded access program. #AVM0703 is a unique proprietary formulation that activates a unique immune response “not targeted by any other available drug” by mobilizing gamma delta TCR invariant TCR double positive T lymphocytes and NKT-like cells and providing hope to DLBCL patients. If you are interested in learning more about how AVM0703 can change the cancer medicine field especially for “no option/frail patients”, or to support us in our mission (we are looking for additional partners/funds) please reach out to Theresa Deisher (Founder and CSO; tdeisher@avmbiotech.com), Dan Spina (Director; dspina@avmbiotech.com), Gerald McLean (Director; jmclean@avmbiotech.com) or Grant Atkins (grant@grantatkins.com). Excited to see you all in Chicago and please don’t forget to stop by our poster #7077 on June 3rd, 9-12 PM. #ASCO2024 #Immunotherapy #GammaDeltaNKTCells #Oncology #DLBCL #TLymphocytes

#microbiotaeducation Notre microbiote est en reflet de notre santé et de nos habitudes de vie. Alors quand notre organisme se détraque sans que ce soit nécessairement dû à notre symbionte, il peut être affecté en retour par notre état physiologique. L'analyse génétique, ADN, de notre microbiote fournit une empreinte génétique qui permet d'identifier et d'analyser les proportions relatives de ses composants. Il est alors possible de comparer ces empreintes entre patients, malades ou non et de relier certaines pathologies entre elles par la signature du microbiote. C'est la teneur de cet article "The microbiome and human cancer" dans Science expliqué par Dr. Amine ZORGANI. Ces signatures génétiques particulières peuvent alors être utiliser comme des marqueurs pour démasquer une pathologie encore non diagnostiquée. Bientôt chez le medecin ou de chez soi, ce sera comme dans Candide: "montre moi ton microbiote et je te dirai qui tu es"... Si vous aimez, Partagez, Commentez, Suivez moi 👍👀❤️

⭐️ Les recommandations sur la gestion des toxicités digestives de la The Multinational Association of Supportive Care in Cancer (MASCC) ⭐️

I am so happy to start this New Year with our work finally being published! This is the result of a long journey, started with my PhD in the Cardiovascular Biology group and successfully finalised by the team of Serena Zacchigna at the ICGEB in Trieste. This is another confirmation of the great potential of #FunSel, the screening strategy that identifies potential therapeutics in the disease models in vivo, developed in the laboratory of Mauro Giacca. To learn more about FunSel, see the latest publication: doi:10.1126/scitranslmed.abo0699 Just some last thoughts. Thanks to all the co-authors. So many bricks are needed to build a solid wall. The list of authors is obviously long, but it just reflects the contribute that is often needed to finalise the publication of an 8-year-long project. Science is a big “in-it together”, and the more we recognise everyone’s skills and expertise, the better works can be shaped. Full publication: doi: 10.1186/s13046-023-02942-4.